文献速递前列腺癌

新诊断转移性前列腺癌患者对减瘤治疗的偏好:IP5-MATTER研究

Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study.
PubMed 文献 · Eur Urol Oncol · 2024-07-06

该研究在英国30家医院开展前瞻性多中心离散选择实验,纳入352例新诊断同步性转移性激素敏感性前列腺癌患者,其中303例完成研究。患者偏好更长生存期和无进展期,对减瘤性前列腺切除术联合全身治疗偏好较低,除非联合转移灶定向治疗。患者愿以尿失禁和疲劳风险各增加10个百分点换取总生存期延长3.4个月(95%CI 2.8-4.3)和2.7个月(95%CI 2.3-3.1)。

要点

  • 患者偏好更长生存期和无进展期。
  • 减瘤性前列腺切除术联合全身治疗偏好较低(Coef. -0.448;95%CI -0.60至-0.29;p<0.001),除非联合转移灶定向治疗。
  • 患者愿以尿失禁风险增加10个百分点换取总生存期延长3.4个月(95%CI 2.8-4.3)。

核心结论

  • 患者接受额外减瘤治疗以换取生存获益,优先考虑保留排尿功能和避免疲劳。

研究设计与样本

  • 前瞻性多中心离散选择实验,在英国30家医院开展,时间为2020年12月3日至2023年1月25日(NCT04590976)。
  • 纳入标准为开始雄激素剥夺治疗后4个月内诊断为新诊断同步性转移性激素敏感性前列腺癌且体能状态0-2。
  • 共入组352例患者,其中303例完成研究;中位年龄70岁(IQR 64-76),前列腺特异性抗原94 ng/ml(IQR 28-370)。
  • 转移分期为M1a 10.9%(33/303)、M1b 79.9%(242/303)、M1c 7.6%(23/303)。
  • 使用误差成分条件logit模型估计治疗属性的偏好和权衡。

主要发现

  • 患者偏好更长生存期和无进展期的治疗。
  • 患者对减瘤性前列腺切除术联合全身治疗偏好较低(Coef. -0.448;95%CI -0.60至-0.29;p<0.001),除非联合转移灶定向治疗。
  • 减瘤性前列腺放疗或消融联合全身治疗、就诊次数、日间手术或增加立体定向消融体部放疗未影响治疗选择。
  • 患者愿以尿失禁风险增加10个百分点换取总生存期延长3.4个月(95%CI 2.8-4.3)。
  • 患者愿以疲劳风险增加10个百分点换取总生存期延长2.7个月(95%CI 2.3-3.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Cytoreductive treatments for patients diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental survival benefits over systemic therapy, but these may lead to added toxicity and morbidity. Our objective was to determine patients' preferences for, and trade-offs between, additional cytoreductive prostate and metastasis-directed interventions. METHODS: A prospective multicentre discrete choice experiment trial was conducted at 30 hospitals in the UK between December 3, 2020 and January 25, 2023 (NCT04590976). The individuals were eligible for inclusion if they were diagnosed with de novo synchronous mHSPC within 4 mo of commencing androgen deprivation therapy and had performance status 0-2. A discrete choice experiment instrument was developed to elicit patients' preferences for cytoreductive prostate radiotherapy, prostatectomy, prostate ablation, and stereotactic ablative body radiotherapy to metastasis. Patients chose their preferred treatment based on seven attributes. An error-component conditional logit model was used to estimate the preferences for and trade-offs between treatment attributes. KEY FINDINGS AND LIMITATIONS: A total of 352 patients were enrolled, of whom 303 completed the study. The median age was 70 yr (interquartile range [IQR] 64-76) and prostate-specific antigen was 94 ng/ml (IQR 28-370). Metastatic stages were M1a 10.9% (33/303), M1b 79.9% (242/303), and M1c 7.6% (23/303). Patients preferred treatments with longer survival and progression-free periods. Patients were less likely to favour cytoreductive prostatectomy with systemic therapy (Coef. -0.448; [95% confidence interval {CI} -0.60 to -0.29]; p < 0.001), unless combined with metastasis-directed therapy. Cytoreductive prostate radiotherapy or ablation with systemic therapy, number of hospital visits, use of a "day-case" procedure, or addition of stereotactic ablative body radiotherapy did not impact treatment choice. Patients were willing to accept an additional cytoreductive treatment with 10 percentage point increases in the risk of urinary incontinence and fatigue to gain 3.4 mo (95% CI 2.8-4.3) and 2.7 mo (95% CI 2.3-3.1) of overall survival, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients are accepting of additional cytoreductive treatments for survival benefit in mHSPC, prioritising preservation of urinary function and avoidance of fatigue. PATIENT SUMMARY: We performed a large study to ascertain how patients diagnosed with advanced (metastatic) prostate cancer at their first diagnosis made decisions regarding additional available treatments for their prostate and cancer deposits (metastases). Treatments would not provide cure but may reduce cancer burden (cytoreduction), prolong life, and extend time without cancer progression. We reported that most patients were willing to accept additional treatments for survival benefits, in particular treatments that preserved urinary function and reduced fatigue.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Connor MJ, Genie M, Dudderidge T, et al. Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study. Eur Urol Oncol. 2024. PMID: 38972831. doi:10.1016/j.euo.2024.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。